EGFR Lung Cancer Patients

AstraZeneca’s pill Tagrisso cut the risk of lung cancer progressing by 70 percent compared to standard chemotherapy in a major clinical trial.

The medicine is designed to help cancer patients with EGFR mutations that are very common in China and other parts of east Asia. In China, nearly half of lung cancer patients are thought to have the EGFR mutation.

Read the article: http://www.reuters.com/article/us-astrazeneca-cancer-pill-idUSKBN13V0VH